A 96-week Randomised, Phase 3 Non-inferiority Study of DTG + TAF + FTC Compared With DTG + TDF + FTC and EFV + TDF+FTC in Patients Infected With HIV-1 Starting First-line Antiretroviral Therapy

Trial Profile

A 96-week Randomised, Phase 3 Non-inferiority Study of DTG + TAF + FTC Compared With DTG + TDF + FTC and EFV + TDF+FTC in Patients Infected With HIV-1 Starting First-line Antiretroviral Therapy

Recruiting
Phase of Trial: Phase III

Latest Information Update: 25 Apr 2017

At a glance

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top